Better management of infection for cardiac patients


The risk of infection following cardiac treatment has greatly reduced at St Andrew’s Toowoomba Hospital with the introduction of new technology.

The hospital has invested in the new TYRX Absorbable Antibacterial Envelope, which is used when inserting cardiovascular implantable devices like a pacemaker or defribillator.

The envelope holds the electronic implantable device, stabilising it and releasing two antibiotics over seven days to reduce surgical-site infections. It is fully absorbed within nine weeks.

The device is particularly effective with high risk patients, including those with diabetes, patients having a revision or upgrade procedure, patients with renal or congestive heart failure, or a previous history of infection, said cardiologist Dr Harish Aikot.

A recent case was 86 year old Geoffrey Luscombe who required a pacemaker, but had recently been hospitalised with a chronic leg infection that led to an amputation.

“While the risk of infection is low for most patients receiving an implantable device, the TYRX envelope offers an extra layer of protection and provides a solution which makes implantable device procedures safer for patients,” said Dr Aikot.

St Andrew’s CEO Ray Fairweather said the hospital is committed to building its comprehensive cardiology services for the Toowoomba community.

“With our state of the art facilities and Dr Aikot’s training and experience in interventional cardiology, treatment for complex cardiac patients is now a reality in Toowoomba,” said Mr Fairweather.


Comments are closed.